Amneal Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Business Address
, , ,
Mailing Address
400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807
Phone
(908) 947-3120
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$72.06M
Net Income
-$70.79M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4/A Insider transaction amendment | March 27, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 26, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
Annual Reports
10-K
February 27, 2026
- Achieved strong performance in FY2024 with 5% revenue growth to $2.31 billion and significant increases in operating and net income.
- Demonstrated improved operational efficiency, leading to expanded operating margins and strong bottom-line growth.
Material Events
8-K
Legal Issue
January 28, 2026
High Impact
- Finalized nationwide opioid settlement resolves major legal uncertainty and provides legal certainty.
- Settlement reduces risk of unpredictable legal judgments and high defense costs, allowing management to focus on core business.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.